Aventis Pharma launches disposable insulin pen
Pharmaceutical company Aventis Pharma Limited toady launched a new prefilled disposable insulin pen diabetic patients and aims at increasing its market share to 9 per cent with this launch.
By PTI |
CHANDIGARH: Pharmaceutical company Aventis Pharma Limited on Friday launched a new prefilled disposable insulin pen diabetic patients and aims at increasing its market share to 9 per cent with this launch.
"SoloSTAR, a disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes and is now available in Chandigarh, Punjab, Haryana and Himachal Pradesh," Aventis Pharma Limited, Senior Director, Susheel Umesh said here on Friday.
" SoloSTARis the result of over four years of intensive research and development. This pen has been designed based on inputs from diabetic patients, their nurses and doctors. Thus we are confident that this will cater to the needs of the patients", he added.
It is an easy-to-use insulin pen brings greater flexibility to patients and an opportunity for earlier initiation of insulin therapy which may contribute to better glycaemic control. This pen is designed in a very convenient manner
to enable patients carry it easily, especially while travelling", added he said.
Currently, the market for insulin stood at Rs. 460 crore and it is growing at a rate of 80 per cent. "We will like to improve our market share to 9 per cent from 7 per cent at present.
"SoloSTAR, a disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes and is now available in Chandigarh, Punjab, Haryana and Himachal Pradesh," Aventis Pharma Limited, Senior Director, Susheel Umesh said here on Friday.
" SoloSTARis the result of over four years of intensive research and development. This pen has been designed based on inputs from diabetic patients, their nurses and doctors. Thus we are confident that this will cater to the needs of the patients", he added.
It is an easy-to-use insulin pen brings greater flexibility to patients and an opportunity for earlier initiation of insulin therapy which may contribute to better glycaemic control. This pen is designed in a very convenient manner
to enable patients carry it easily, especially while travelling", added he said.
Currently, the market for insulin stood at Rs. 460 crore and it is growing at a rate of 80 per cent. "We will like to improve our market share to 9 per cent from 7 per cent at present.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
